Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 50090-7442

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 50090-7442). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C:\users\ra\desktop\1.jpg (5a5eca60 Figure 01)

A line graph showing the percentage of subjects with systolic blood pressure (SBP) below 140 mmHg versus baseline SBP values ranging from 140 to 180 mmHg. The graph compares four groups: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, each represented by distinct markers and lines.*

FDA Label Image

C:\users\ra\desktop\2.jpg (5a5eca60 Figure 02)

A line graph comparing the percentage of patients with diastolic blood pressure (DBP) below 90 mmHg against baseline DBP values from 90 to 110 mmHg. Four treatments are shown: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, with Valsartan-HCTZ showing the highest percentage achieving DBP < 90 mmHg.*

FDA Label Image

C:\users\ra\desktop\3.jpg (5a5eca60 Figure 03)

A line graph showing the percentage of subjects with systolic blood pressure (SBP) below 130 mmHg across different baseline SBP values (140 to 180 mmHg). It compares four groups: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo. Valsartan-HCTZ shows the highest percentage response compared to the other groups.*

FDA Label Image

C:\users\ra\desktop\4.jpg (5a5eca60 Figure 04)

A line graph depicting the percentage of subjects achieving diastolic blood pressure below 80 mmHg (% DBP <80) versus baseline diastolic blood pressure (DBP in mmHg). The graph compares four groups: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, each represented by distinct markers. The data show a decreasing trend in % DBP <80 as baseline DBP increases for all groups.*

FDA Label Image

C:\users\ra\desktop\5.jpg (5a5eca60 Figure 05)

Chemical structure of valsartan, the active ingredient in the combination drug valsartan and hydrochlorothiazide.*

FDA Label Image

C:\users\ra\desktop\6.jpg (5a5eca60 Figure 06)

Chemical structure diagram depicting a molecular structure with labeled atoms including chlorine (Cl) and sulfonamide (SO2NH) groups, consistent with the active ingredients in valsartan and hydrochlorothiazide tablets.*

FDA Label Image

Label Image (Lbl500907442)

VALSARTAN AND HYDROCHLORTHIAZIDE 320 mg/12.5 mg oral film-coated tablets packaged by A-S Medication Solutions. The label indicates storage instructions to keep the tablets at 68 to 77 degrees Fahrenheit and protect from moisture. The bottle contains 90 tablets and includes the product NDC 50090-7442.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.